最新消息 生華科皮膚癌一期臨床完成 末期患者多活一年病況穩定 Aug 25 2023 最新消息 公司聲明 Aug 10 2023 最新消息 生華科在台啟動新冠二期臨床 布局不限定病毒、免疫疾病領域 Apr 28 2023 媒體報導 生華科在台啟動新冠新藥二期臨床 目標下季取得初步數據 Apr 28 2023 媒體報導 生華科持續開發新冠新藥 向台灣申請二期臨床試驗 Mar 01 2023 媒體報導 生華科(6492)新藥CX-5461繼獲輝瑞認同後，再入選美國NIH抗癌國家隊全速推進新藥上市 Dec 01 2022 期刊 Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study Sep 24 2022 期刊 Protein kinase CK2: a potential therapeutic target for diverse human diseases Jul 20 2021 期刊 Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study. Jan 12 2021